Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE

Cryoablation

Cryoablation is performed under US or CT guidance per Investigator decision.

DRUG

Tislelizumab

a PD-1 immune check inhibitor

DRUG

Lenvatinib

Lenvatinib capsules

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER